Itacitinib adipate, a selective JAK1 inhibitor developed by Incyte Corporation, is undergoing clinical trials aimed at treating BOS, particularly in patients following HCT [94]. This evidence concerns the gene JAK1 and Buschke-Ollendorff syndrome.